HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

tartrate salt cis- 1R- (4'- pyrrolidinoethoxyphenyl)- 2S- phenyl- 6- hydroxy- 1,2,3,4- tetrahydronaphthalene (Lasofoxifene)

structure in first source
Also Known As:
Lasofoxifene; cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt; CP 336156; CP-336,156; LAS estrogen receptor modulator
Networked: 61 relevant articles (9 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Gennari, Luigi: 9 articles (04/2011 - 10/2005)
2. Thompson, David D: 6 articles (05/2012 - 04/2004)
3. Merlotti, Daniela: 5 articles (02/2011 - 09/2006)
4. Nuti, Ranuccio: 5 articles (02/2011 - 09/2006)
5. Jordan, V Craig: 4 articles (05/2013 - 01/2006)
6. Vukicevic, Slobodan: 4 articles (05/2012 - 02/2010)
7. Reid, David M: 4 articles (05/2012 - 02/2010)
8. Eastell, Richard: 4 articles (05/2012 - 02/2010)
9. Thompson, John R: 3 articles (05/2012 - 10/2010)
10. LaCroix, Andrea Z: 3 articles (05/2012 - 02/2010)

Related Diseases

1. Postmenopausal Osteoporosis
2. Osteoporosis
3. Atrophy
4. Breast Neoplasms (Breast Cancer)
5. Stroke (Strokes)
02/25/2010 - "Lasofoxifene at a dose of 0.25 mg per day, as compared with placebo, was associated with reduced risks of vertebral fracture (16.0 vs. 22.4 cases per 1000 person-years; hazard ratio, 0.69; 95% CI, 0.57 to 0.83) and stroke (2.4 vs. 3.9 cases per 1000 person-years; hazard ratio, 0.61; 95% CI, 0.39 to 0.96) Both the lower and higher doses, as compared with placebo, were associated with an increase in venous thromboembolic events (3.8 and 2.9 cases vs. 1.4 cases per 1000 person-years; hazard ratios, 2.67 [95% CI, 1.55 to 4.58] and 2.06 [95% CI, 1.17 to 3.60], respectively). "
10/26/2010 - "In the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary heart disease (CHD) events and stroke, whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke. "
02/25/2010 - "Lasofoxifene at a dose of 0.5 mg per day, as compared with placebo, was associated with reduced risks of vertebral fracture (13.1 cases vs. 22.4 cases per 1000 person-years; hazard ratio, 0.58; 95% confidence interval [CI], 0.47 to 0.70), nonvertebral fracture (18.7 vs. 24.5 cases per 1000 person-years; hazard ratio, 0.76; 95% CI, 0.64 to 0.91), ER-positive breast cancer (0.3 vs. 1.7 cases per 1000 person-years; hazard ratio, 0.19; 95% CI, 0.07 to 0.56), coronary heart disease events (5.1 vs. 7.5 cases per 1000 person-years; hazard ratio, 0.68; 95% CI, 0.50 to 0.93), and stroke (2.5 vs. 3.9 cases per 1000 person-years; hazard ratio, 0.64; 95% CI, 0.41 to 0.99). "
02/25/2010 - "In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events. "
01/01/2009 - "Lasofoxifene reduced the risk of coronary heart disease events as well as the risk of stroke, while the risk of deep vein thrombosis remained in line with other SERMs. "

Related Drugs and Biologics

1. Selective Estrogen Receptor Modulators (SERM)
2. Raloxifene (Evista)
3. bazedoxifene acetate
4. 2- (4- (4- chloro- 1,2- diphenyl- but- 1- enyl)phenoxy)ethanol
5. Estrogens (Estrogen)
6. Tamoxifen
7. Toremifene (Fareston)
8. Steroid Receptors (Steroid Receptor)
9. Estrogen Receptors
10. Aromatase Inhibitors

Related Therapies and Procedures

1. Stents
2. Chemoprevention